MétaCan
Menu
Back to cohort
Record W4417001845 · doi:10.1182/blood-2025-761

Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium

2025· article· en· W4417001845 on OpenAlexaff
Thai Hoa Tran, Meenakshi Devidas, Leyna Xoi, Andishe Attarbaschi, Judith M. Boer, Gunnar Cario, Giovanni Cazzaniga, Gabriele Escherich, Yoshihiro Gocho, Mats Heyman, Stephen P. Hunger, Hiroto Inaba, Gábor Kovács, Anthony V. Moorman, Charles G. Mullighan, Kjeld Schmiegelow, Jan Starý, Tomasz Szczepański, David T. Teachey, Andrea Biondi, Mignon L. Loh, Rob Pieters, Sarah Elitzur

Bibliographic record

VenueBlood · 2025
Typearticle
Languageen
FieldMedicine
TopicAcute Lymphoblastic Leukemia research
Canadian institutionsCentre Hospitalier Universitaire Sainte-Justine
Fundersnot available
KeywordsCohortPDGFRBRetrospective cohort studyLymphoblastic LeukemiaAcute lymphocytic leukemiaDasatinibWhite blood cellTyrosine kinaseETV6

Abstract

fetched live from OpenAlex

Abstract Introduction: ABL-class acute lymphoblastic leukemia (ALL) is characterized by rearrangements of ABL1 or other ABL-family tyrosine kinases that drive uncontrolled cell growth. Children with ABL-class B-ALL treated without tyrosine kinase inhibitors (TKIs) achieve 5-year event-free survival (EFS) of 59% (Den Boer et al., Lancet Haematology, 2021). The addition of TKIs to chemotherapy-based therapy has substantially improved outcomes for BCR::ABL1-positive B-ALL. ABL-class fusions occur in 5-10% of T-cell ALL (T-ALL) cases, and small case series report aggressive disease with poor outcomes. However, comprehensive outcome data for pediatric ABL-class T-ALL remain limited. We describe the clinical characteristics, outcomes, and prognostic factors of children with T-ALL harboring ABL-class fusions. Methods: We conducted a multinational retrospective cohort study encompassing 14 collaborative groups from the Ponte di Legno (PdL) consortium. Demographic, clinical, treatment, and outcome data were collected for newly-diagnosed pediatric T-ALL patients harboring ABL-class fusions between 1987 and 2023. Results: The cohort comprised 196 patients with ABL-class T-ALL: 16 (8.2%) with BCR::ABL1 fusions, 136 (69.4%) with NUP214::ABL1 fusions and the remaining 44 (22.4%) with other ABL-class fusions “other-ABL” involving non-NUP214 ABL1 (n=28), ABL2 (n=2), PDGFRA (n=6) and PDGFRB (n=8). The median age at diagnosis was 8 years (range: 1 – 22 years). The median white blood cell (WBC) count was 82,600 cells/mm³ (range: 2,000-1,471,000). Patients with other-ABL had higher median WBC compared to those with BCR::ABL1 or NUP214::ABL1 fusions (217,500 vs. 39,000 vs. 72,400; p=0.0129). Of those with available treatment dates, 77.5% were treated in 2010 or later. Central nervous system (CNS) involvement was classified as CNS-2 in 35 patients (18.7%) and CNS-3 in 7 patients (3.7%). Cranial radiotherapy was administered to 35.9% of patients. Consolidation with hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) was performed in 18.6% of patients. TKIs were administered to 27 of 157 (17.2%) patients with available treatment data: BCR::ABL1 (n=9), NUP214::ABL1 (n=9) and other-ABL (n=9). Overall, 149/167 (89.2%) patients achieved morphologic complete remission (CR). Failure to achieve CR was highest among patients with other-ABL (25.0%) compared to those with BCR::ABL1 (15.4%) and NUP214::ABL1 (4.5%) fusions; p=0.0025. Among 140 patients with available end of induction (EOI) minimal residual disease (MRD) data, 45 (32.1%) patients were EOI MRD negative at the 0.01% threshold, 50 (35.7%) patients had MRD levels of 0.01% to <1% and 45 (32.1%) patients had levels ≥1%. With a median follow-up of 6.1 years for the 162 patients with outcome data, the 5-year EFS and overall survival (OS) for the entire cohort were 78.1% (95% CI 71.7% - 85.2%) and 83.6% (95% CI 77.7% - 90.1%), respectively. By fusion subtype, 5-year EFS and OS were 67.7% (95% CI 46.0% - 99.7%) and 75.5% (95% CI 54.9% - 100%) for BCR::ABL1; 80.8% (95% CI 73.2% - 89.3%) and 85.7% (95% CI 78.7% - 93.3%) for NUP214::ABL1; and 74.6% (95% CI 62.2% - 89.6%) and 81.2% (95% CI 69.5% - 94.9%) for other-ABL. The 5-year cumulative incidence of relapse was 16.2±10.5% for patients with BCR::ABL1, 14.1±3.6% for patients with NUP214::ABL1 and 13.0± 5.4% for patients with other-ABL. Among patients with non-BCR::ABL1 ABL-class T-ALL, the 5-year EFS was 70.0% (95% CI 51.0%- 96.2%) for those treated with TKIs (n=18) versus 79.8% (95% CI 72.5% - 87.7%) for those not treated with TKIs (n=117); p=0.5082. Among the 18 TKI-treated patients, there were 2 induction failures, 2 relapses and 1 treatment-related death. In univariate Cox regression analyses, only HSCT in CR1 (HR=3.21; p=0.006) was associated with inferior EFS for patients with non-BCR::ABL1 ABL-class T-ALL. In univariate analyses, none of the variables were significantly associated with OS. Conclusion: This large international cohort study has established the baseline characteristics and outcomes of children with ABL-class T-ALL. In contrast to ABL-class B-ALL, ABL-class T-ALL demonstrated comparable outcomes to non-ABL-class T-ALL. We could not demonstrate the benefit of TKI treatment among patients with non-BCR::ABL1 ABL-class T-ALL, although numbers in the TKI group were small. These findings provide important baseline data for future prospective studies evaluating novel therapies in pediatric ABL-class T-ALL.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.015
Threshold uncertainty score0.031

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.290
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBloodSame topicAcute Lymphoblastic Leukemia researchFrench-language works237,207